Ang II enhances tubular cell Ets-1 expression and associated down stream signaling is mediated through AT1 receptors

REFERENCES

• Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med. 1988;318:1657–1666.
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116:288–296.
   PubMed Web of Science ®Google Scholar
• Fogo AB. Progression and potential regression of glomerulosclerosis. Kidney Int. 2001;59:804–819.
   PubMed Web of Science ®Google Scholar
• Michael AF, Keane WF, Raij L, Vernier RL, Mauer SM. The glomerular mesangium. Kidney Int. 1980;17:141–154.
   PubMed Web of Science ®Google Scholar
• Matsusaka T, Hymes J, Ichikawa I. Angiotensin in progressive renal diseases: Theory and practice. J Am Soc Nephrol. 1996;7:2025–2043.
   PubMed Web of Science ®Google Scholar
• Egido J. Vasoactive hormones and renal sclerosis. Kidney Int. 1996;49:578–598.
   PubMed Web of Science ®Google Scholar
• Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int. 2000;57:1803–1817.
   PubMed Web of Science ®Google Scholar
• Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int. 2005;67:799–812.
   PubMed Web of Science ®Google Scholar
• Wolf G, Butzmann U, Wenzel UO. The renin–angiotensin system and progression or renal disease: From hemodynamics to cell biology. Nephron Physiol. 2003;93:3–13.
   Google Scholar
• Vaziri ND, Bai Y, Ni Z, Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J Pharmacol Exp Ther. 2007;323:85–93.
   PubMed Web of Science ®Google Scholar
• Manea A, Manea SA, Gafencu AV, Raicu M, Simionescu M. AP-1-dependent transcriptional regulation of NADPH oxidase in human aortic smooth muscle cells: Role of p22phox subunit. Arterioscler Thromb Vasc Biol. 2008;28:878–885.
   PubMed Web of Science ®Google Scholar
• Banes-Berceli AK, Shaw S, Ma G, Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol. 2006;291:F116–F121.
   PubMed Web of Science ®Google Scholar
• Giasson E, Servant MJ, Meloche S. Cyclic AMP-mediated inhibition of angiotensin II-induced protein synthesis is associated with suppression of tyrosine phosphorylation signaling in vascular smooth muscle cells. J Biol Chem. 1997;272:26879–26886.
   PubMed Web of Science ®Google Scholar
• Muller DN, Dechend R, Mervaala EM, NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000;35:193–201.
   PubMed Web of Science ®Google Scholar
• Theuer J, Dechend R, Muller DN, Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord. 2002;2:3.
   PubMedGoogle Scholar
• Zhan Y, Brown C, Maynard E, Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest. 2005;115:2508–2516.
   PubMed Web of Science ®Google Scholar
• Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. Eur J Biochem. 1993;211:7–18.
   PubMedGoogle Scholar
• Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer. 2003;2:29.
   PubMedGoogle Scholar
• Garvie CW, Pufall MA, Graves BJ, Wolberger C. Structural analysis of the autoinhibition of Ets-1 and its role in protein partnerships. J Biol Chem. 2002;277:45529–45536.
   PubMed Web of Science ®Google Scholar
• Risau W, Flamme I. Vasculogenesis. Annu. Rev. Cell Dev Biol. 1995;11:73–91.
   PubMed Web of Science ®Google Scholar
• Oda N, Abe M, Sato Y. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. J Cell Physiol. 1999;178: 121–132.
   PubMed Web of Science ®Google Scholar
• Nakano T, Abe M, Tanaka K, Angiogenesis inhibition by transdominant mutant Ets-1. J Cell Physiol. 2000;184: 255–262.
   PubMed Web of Science ®Google Scholar
• Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: Roles of apoptosis, inflammation, and fibrosis [review]. Hypertension. 2001;38:581–587.
   PubMed Web of Science ®Google Scholar
• Zhang C, Kavurma MM, Lai A, Khachigian LM. Ets-1 protects vascular smooth muscle cells from undergoing apoptosis by activating p21WAF1/Cip1: ETS-1 regulates basal and inducible p21WAF1/Cip transcription via distinct cis-acting elements in the p21WAF/Cip1 promoter. J Biol Chem. 2003;278:27903–27909.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999;99:3050–3055.
   PubMed Web of Science ®Google Scholar
• Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin–angiotensin inhibition. Kidney Int. 1997;51:164–172.
   PubMed Web of Science ®Google Scholar
• Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol. 2002;283:F209–F220.
   PubMed Web of Science ®Google Scholar
• Ma LJ, Fogo AB. Angiotensin as inducer of plasminogen activator inhibitor-1 and fibrosis. Contrib Nephrol. 2001;135: 161–170.
   Web of Science ®Google Scholar
• Kaikita K, Fago AB, Ma L, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001;104:839–844.
   PubMed Web of Science ®Google Scholar
• Taal MW, Zandi-Nejad K, Weening B, Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int. 2000;58:1664–1676.
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega M, Bustos C, Hernández-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol. 1998;161:430.
   PubMed Web of Science ®Google Scholar
• Anders HJ, Belemezova E, Eis V, Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol. 2004;15:1504–1513.
   PubMed Web of Science ®Google Scholar
• Morrissey JJ, Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol. 1998;274:F580– F586.
   PubMedGoogle Scholar